Skip to Content

Nivolumab + Cabozantinib Remains Standard of Care in First-Line Treatment for Advanced Renal Cell Carcinoma

In this MEDtalk, Maria Teresa Bourlon presents the updated efficacy in the intention-to-treat population at 55-month median follow-up on the CheckMate 9ER phase 3 trial. The results show that the combination therapy with nivo+cabo continues to maintain meaningful long-term benefits in efficacy endpoints, such as progression-free survival, overall survival, and overall response rates.

Maria Teresa Bourlon

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top